Form 4: Humacyte Executive Shamik J. Parikh Reports Stock Option Grant

Chief Medical Officer Shamik J. Parikh of Humacyte, Inc. reports the acquisition of stock options.

Summary

• On January 21, 2025, Shamik J. Parikh, Chief Medical Officer of Humacyte, Inc., acquired stock options for 283,101 shares.
• The exercise price of these options is $4.56.
• The options vest over time, with the first 25% becoming exercisable on January 21, 2026.
• Thereafter, 1/48th of the options will vest monthly until January 21, 2029.
• The options expire on January 21, 2035.
• Following the transaction, Parikh directly owns options for 283,101 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard executive compensation disclosure. The grant of options can be seen as a positive sign of incentivizing management, but it also represents potential future dilution for shareholders.

Positives

• The granting of stock options to a key executive like the Chief Medical Officer can align their interests with those of the shareholders, incentivizing them to work towards the company's long-term success.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align their interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• The vesting schedule and exercise price would need to be compared against similar companies and executive roles to determine if they are in line with industry norms.
• Companies like Amgen, Gilead, and Regeneron also utilize stock options as part of their executive compensation packages.

Stakeholder Impact

• Shareholders may experience dilution if the options are exercised.
• Employees may view the option grant as a positive sign of the company's commitment to its leadership.

Key Dates